SLC38A2 Antibody

What is SLC38A2 and why is it an important research target?

SLC38A2 (solute carrier family 38 member 2) is a sodium-dependent neutral amino acid transporter with multiple biological roles. It is also known as SNAT2, ATA2, SAT2, PRO1068, and amino acid transporter 2. This protein transports small and medium neutral amino acids, particularly alanine, serine, proline, and glutamine .

The protein is important in research for several reasons:

• It is ubiquitously expressed in mammalian tissues

• It plays critical roles in amino acid homeostasis

• It functions in cellular osmotic regulation

• It has been implicated in type II diabetes and cancer pathophysiology

• It is upregulated under hypertonic conditions and during amino acid deprivation

• It contributes to medullary protection against hyperosmolarity-induced ferroptosis

SLC38A2 has a molecular weight of approximately 56 kDa, though some researchers report observing bands at both 45 kDa and 56 kDa in Western blot applications .

What applications are most suitable for SLC38A2 antibodies?

Based on available commercial antibodies, the following applications have been validated for SLC38A2 antibodies:

For Western blot applications, recommended dilutions typically range from 1:400 to 1:1000 depending on the specific antibody product . For optimal results in immunohistochemistry, antigen retrieval with TE buffer pH 9.0 is often recommended, though citrate buffer pH 6.0 may be used as an alternative .

How should I select the appropriate SLC38A2 antibody for my specific research needs?

When selecting an SLC38A2 antibody, consider these research-oriented criteria:

• Epitope location: Different antibodies target different regions of SLC38A2. For instance:

  • N-terminal specific antibodies (amino acids 21-150, 1-76, 25-40)

  • Internal region-specific antibodies

  This is particularly important when studying different isoforms or when specific domains are of interest.

• Species reactivity: Consider cross-reactivity profiles based on your experimental model:

  • Human-only reactive antibodies

  • Multi-species reactive antibodies (human, mouse, rat)

  • Some antibodies show extended reactivity to dog, cow, sheep, pig, horse, and rabbit models

• Validated applications: Ensure the antibody has been validated for your specific application

  • Some antibodies are optimized for Western blot but may not perform as well in IHC

  • Flow cytometry applications require specific validation data

• Validation data: Review existing literature citing the antibody or examine validation data provided by suppliers, particularly when blocking peptides have been used to confirm specificity .

For robust experimental design, it's advisable to validate antibody specificity in your specific experimental system before proceeding with extensive studies.

What are the optimal conditions for Western blot detection of SLC38A2?

For optimal Western blot detection of SLC38A2, consider the following protocol adjustments:

• Sample preparation:

  • For brain tissue samples, incubation at 37°C improves detection

  • Use membrane fractions for enrichment when studying neuronal samples

• Expected band size:

  • Primary band at approximately 56 kDa

  • Some researchers report observing bands at both 45 kDa and 56 kDa

  • Variation may be due to post-translational modifications or isoforms

• Antibody dilution:

  • Typical working dilutions range from 1:400 to 1:1000

  • When using HRP-conjugated secondary antibodies, they should be diluted 1:50,000-1:100,000

• Buffer systems:

  • PBS-based buffer systems with 0.09% sodium azide and 2% sucrose have shown good results

  • Some antibodies are provided in PBS/50% glycerol, pH 7.2 for stability

• Controls:

  • Use blocking peptides as negative controls when available

  • Brain lysates from rat or mouse serve as reliable positive controls

How can SLC38A2 antibodies be used in cancer research applications?

SLC38A2 has emerged as an important target in cancer research, particularly in studies examining glutamine dependency in tumors. These methodological approaches have proven valuable:

• Tumor microenvironment studies:

  • Use SLC38A2 antibodies to analyze differential expression between tumor cells and immune cells

  • Research has demonstrated higher SLC38A2 expression in tumor cells compared to dendritic cells (DCs) and T cells

  • Dual immunostaining with immune cell markers can reveal competitive glutamine uptake dynamics

• Functional analysis in cancer models:

  • Following SLC38A2 knockout in tumor cells (e.g., MC38 or B16-OVA cell lines), researchers have demonstrated:

    • Reduced glutamine uptake

    • Impaired tumor growth

    • Enhanced anti-tumor immunity

• Translational applications:

  • SLC38A2 inhibition selectively targets glutamine-dependent breast cancer cell lines

  • Antibodies can be used to screen for SLC38A2 expression as a potential biomarker for glutamine dependency

A key methodological approach involves comparing SLC38A2 expression between tumor and surrounding immune cells using both flow cytometry and immunohistochemistry methods, as SLC38A2 represents a "competitive metabolic checkpoint" between tumor cells and immune cells .

What troubleshooting approaches are recommended for inconsistent SLC38A2 antibody results?

When encountering inconsistent results with SLC38A2 antibodies, consider these methodological troubleshooting approaches:

• Antibody specificity concerns:

  • Validate using blocking peptides when available

  • Consider using genetically modified samples (SLC38A2 knockout or overexpression) as controls

  • Multiple bands may represent isoforms or post-translational modifications

• Sample-specific issues:

  • SLC38A2 expression is regulated by osmotic conditions and amino acid availability

  • Control for culture conditions in cell experiments (osmolarity, amino acid availability)

  • For tissue samples, note hydration status of source animals

• Technical optimizations:

  • For brain tissues, incubation at 37°C improves detection

  • For membrane proteins, optimization of extraction buffers is critical

  • Antigen retrieval conditions significantly impact IHC results (TE buffer pH 9.0 versus citrate buffer pH 6.0)

• Signal localization issues:

  • SLC38A2 localizes to both cell membrane and cytoplasm

  • Co-staining with membrane markers like Na⁺-K⁺ ATPase can help confirm proper membrane localization

  • Studies using SLC38A2-EGFP fusion constructs have demonstrated this dual localization pattern

How are SLC38A2 antibodies being used to study ferroptosis mechanisms?

Recent research has revealed important connections between SLC38A2 and ferroptosis, particularly in renal medullary cells. These methodological approaches have proven valuable:

• Tissue-specific expression analysis:

  • Immunohistochemical analysis using SLC38A2-specific antibodies has revealed that the protein is ubiquitously expressed in most renal tubule segments

  • Higher expression levels are observed in renal medullary collecting duct (MCD) epithelial cells

• Response to osmotic stress:

  • Water-deprived mouse models show upregulation of SLC38A2 mRNA and protein

  • Antibody-based detection methods have confirmed this increased expression at the protein level

• Mechanistic studies:

  • SLC38A2 has been demonstrated to protect MCD cells from hyperosmolarity-induced ferroptosis

  • This protection mechanism involves activation of the mTORC1 pathway

  • SLC38A2 knockout mice exhibit significantly increased medullary ferroptosis following water restriction

These findings position SLC38A2 as an important osmoresponsive gene in the renal medulla, with implications for understanding kidney function in water homeostasis.

What considerations are important when using SLC38A2 antibodies for co-localization studies?

When designing co-localization studies with SLC38A2 antibodies, consider these methodological approaches:

• Subcellular localization patterns:

  • SLC38A2 localizes to both plasma membrane and cytoplasm

  • Studies using SLC38A2-EGFP fusion proteins have confirmed this dual localization pattern

  • When performing co-localization, select appropriate compartment markers:

    • Na⁺-K⁺ ATPase for plasma membrane

    • Organelle-specific markers for potential intracellular pools

• Cell-type specific considerations:

  • In neuronal tissues, SLC38A2 shows enrichment in neuronal outlines within the ventromedial hypothalamus

  • In spinal cord sections, neuronal outlines in the ventral horn show strong immunoreactivity

  • For renal tissue, SLC38A2 shows higher expression in medullary collecting duct epithelial cells compared to other segments

• Technical optimization:

  • For fluorescence co-localization, consider secondary antibody selection to prevent spectral overlap

  • For tissues with high autofluorescence (like kidney), additional blocking steps may be required

  • Validation with blocking peptides is strongly recommended for co-localization studies

• Physiological considerations:

  • SLC38A2 expression and localization can change under different physiological conditions

  • Water deprivation models show increased expression

  • Amino acid starvation can also alter expression patterns

What approaches have been successful for bacterial production of recombinant SLC38A2 protein?

Recent advances have enabled bacterial overproduction of functionally active human SLC38A2, providing valuable insights for researchers working with this challenging membrane protein:

• Vector and expression system optimization:

  • The pET-28-Mistic vector system has proven successful

  • BL21 codon plus RIL strain transformation with the recombinant construct addresses codon usage issues

  • Addition of a Mistic tag at the N-terminus is crucial for overexpression and purification

• Culture conditions for optimal expression:

  • 0.5% glucose supplementation is critical

  • Oxygen availability plays a key role in expression levels

  • Lower ratios between culture and flask volumes improve expression

• Purification approach:

  • On-column cleavage of the hSNAT2-Mistic chimera

  • Nickel-chelating affinity chromatography

  • Achieved yields of approximately 60 mg/Liter cell culture

• Functional validation:

  • The purified protein can be reconstituted in proteoliposomes in an active form

  • Right-side-out orientation with respect to the native membrane can be achieved

  • Functional activity can be confirmed through transport assays

How can researchers distinguish between different SLC38A2 isoforms or post-translational modifications?

For detailed characterization of SLC38A2 isoforms or post-translational modifications, consider these methodological approaches:

• Antibody selection strategy:

  • Choose antibodies targeting different epitopes within SLC38A2:

    • N-terminal specific antibodies (AA 21-150, 1-76, 25-40)

    • Internal region antibodies

    • C-terminal antibodies

  • Compare banding patterns across these antibodies to identify potential isoforms

• Western blot optimization:

  • Use gradient gels (4-12% or 4-20%) for better separation of similar-sized isoforms

  • Extended run times can help resolve closely migrating bands

  • Some researchers report observing bands at both 45 kDa and 56 kDa, which may represent different isoforms or modified forms

• Treatment conditions to detect modifications:

  • Phosphatase treatment to identify phosphorylated forms

  • Glycosidase treatment to identify glycosylated forms

  • Compare banding patterns under different osmotic stress conditions, as SLC38A2 is regulated by osmotic pressure

• Advanced techniques:

  • Mass spectrometry following immunoprecipitation with SLC38A2 antibodies

  • 2D gel electrophoresis to separate isoforms based on both size and charge

  • Epitope mapping using peptide arrays can help identify specific regions involved in modifications